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to bone marrow-derived stromal (MdS) cells. The bone marrow
mesenchyme supports hematopoietic stem cells and progenitors in
vivo and in vitro. The AdS are readily accessible from subcutaneous
fat but have not been fully characterized for hematopoietic sup-
port. We now directly compare the relative capacities of allogeneic
AdS and MdS to support hematopoiesis. In total, 4 preparations of
AdS and 4 preparations of MdS were used to complete these
studies. Support for primitive hematopoietic progenitors was mon-
itored in 5-week long-term culture (LTC) assays. CD34CD38neg
cells were puriﬁed from umbilical cord blood (UCB, n  8) to
establish duplicate cultures with 100 hematopoietic progenitors per
well in standard Dexter-type media. LTC cultures on MdS gave
rise to 67.1  19.8 CFU after 5 weeks. Parallel cultures on AdS
gave rise to 26.6  11.4 CFU. These frequencies approach statis-
tical signiﬁcance (p  0.054). Importantly, however, 30% of the
cultures initiated on AdS failed to support LTC. Thus, 100 CD34
CD38neg cells may deﬁne a limit-dilution for LTC activity on AdS
cells. In contrast, all cultures initiated on MdS supported LTC. In
shorter-term assays, parallel cultures were established using 10,000
CD34 linneg UCB cells for 12 days. The cultures were established
in DMEM/F12 media containing 10% serum. No exogenous cy-
tokines were used. The results are tabulated below. AdS and MdS
supported similar expansions of total hematopoietic (CD45) cells.
However, cultures established on MdS maintained higher percent-
ages of CD34 cells over the 12 day time course. Not surprisingly,
there was a strong association between the percentages of CD34
cells and the frequencies of CFU present at day 12 (AdS, r  0.81;
MdS, r  0.85). However, without exogenous cytokines these
stroma maintained but did not expand the total content of CFU.
Finally, both AdS and MdS encouraged the outgrowth of lymphoid
progenitors as monitored by the presence of CD7 CD34neg cells
as well as by the growth of NK (CD56) cells in secondary
cultures. Higher percentages of CD7 cells were noted on AdS
than on MdS. In total, these data suggest that AdS and MdS
provide similar hematopoietic support, although subtle distinctions
were noted. These studies provide a model that can be manipulated
to optimize hematopoietic expansion ex vivo.
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THROMBOTIC MICROANGIOPATHY (TMA) FOLLOWING ALLOGENEIC
STEM-CELL TRANSPLANTATION (SCT) IN THE ERA OF REDUCED-IN-
TENSITY CONDITIONING: THE INCIDENCE IS NOT REDUCED
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus
TMA is one of the most severe complications of SCT. Endothe-
lial cell injury caused by the toxic effects of high-dose chemo-
radiotherapy is likely the primary event in the pathogenesis. The
incidence, clinical settings, and risk factors for TMA in the era of
nonmyeloablative and reduced intensity conditioning (NST/RIC)
have not been well deﬁned. We collected data on 147 consecutive
SCTs for various hematologic malignancies. The diagnosis of
TMA required thrombocytopenia, elevated LDH level and frag-
mented red cells in peripheral blood ﬁlm. TMA occurred following
22 SCTs with a projected incidence of 20  4% in a median of 30
days after SCT. TMA occurred in 3 overlapping clinical settings:
classical multifactorial TMA, TMA associated with severe hepatic
GVHD, and TMA associated with second allogeneic SCT, with a
projected incidence of 8  3%, 73  14%, and 70  16% of pts
at risk, respectively. TMA occurred following 23  6% of NST/
RIC (14 of 84) and 16  5% of myeloablative conditioning (8 of
63) (p NS). Univariant analysis determined SCT from unrelated
donors, SCT during advanced/ active disease, second SCT within
6 months of a prior SCT, and acute GVHD as risk factors for
TMA. The last two factors remained signiﬁcant in a multivariant
model with hazard ratios of 6.4 and 14.5, respectively. Therapy
included withdrawal or reduction of cyclosporine dose and infusion
of cryoprecipitate poor plasma with a response rate of 23 percent.
4 of the non-responders were treated with plasma exchange and 2
responded. Overall, 32% of pts responded to any line of therapy.
Only 4 pts are currently alive. Ten died of complications related to
acute GVHD. Five died of bleeding complications; 4 of diffuse
alveolar hemorrhage (DAH) and one of CNS bleeding. One pt
died of cerebral TMA with refractory convulsions. The peri-TMA
mortality rate was 68  10%. Two additional pts later died of
relapse. SCT-associated TMA is a relatively common complication
with unsatisfactory therapy and grim prognosis. Fludarabine-based
NST/RIC does not confer a lesser risk for TMA. This unexpected
observation relates in part to the selective use of NST/RIC in older
pts, pts having a second SCT, extensive prior therapy or unrelated
donor SCT, all risk factors for TMA. Fludarabine, a major con-
stitute of these regimens, may also be involved in causing endo-
thelial damage and increasing the risk for TMA. Further explora-
tion of novel preventive and therapeutic measurements is required
in high-risk settings.
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EVALUATION OF THE PLATELET-SPECIFIC ANTIBODY RESPONSE IN
THROMBOCYTOPENIA FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Yamazaki, R.1,2, Mori, T.1, Kuwana, M.2, Okazaki, Y.2, Kawakami,
Y.2, Ikeda, Y.1, Okamoto, S.1 1. Division of Hematology, Department of
Internal Medicine; 2. Division of Cellular Signaling, Institute for Ad-
vanced Medical Research, Keio University School of Medicine, Shinjuku-
ku, Tokyo, Japan
Thrombocytopenia is a common complication early and late after
allogeneic hematopoietic stem cell transplantation (allo-HSCT),
but its etiologies are largely unknown. In this study, a role of
anti-platelet antibody response in patients with thrombocytopenia
after allo-HSCT was examined by detecting antibodies to glyco-
protein IIb/IIIa (GPIIb/IIIa), a major platelet-speciﬁc autoantigen
in patients with idiopathic thrombocytopenic purpura (ITP). Fifty-
six patients with hematological malignancies who received allo-
HSCT were enrolled. Of these, 35 patients suffered from pro-
longed thrombocytopenia. As controls, 78 ITP patients and 52
healthy donors were also examined. Circulating B cells secreting
anti-GPIIb/IIIa antibodies were measured using enzyme-linked
immunospot assay, and anti-GPIIb/IIIa antibodies in platelet elu-
ates and plasma were detected by enzyme-linked immunosorbent
assay. Frequency of anti-GPIIb/IIIa antibody-producing B cells in
allo-HSCT patients was comparable to that in ITP patients, but
was signiﬁcantly higher than that in healthy donors (5.8  6.4 vs
8.2  5.4 and 0.4  0.3 /105PBMCs; p  0.02 and 0.001,respec-
tively). In allo-HSCT patients, anti-GPIIb/IIIa antibody-produc-
ing B cell frequency was signiﬁcantly greater in patients with
thrombocytopenia than in those without (7.3  7.3 vs 3.3  3.6;
p  0.009). Moreover, platelet count was negatively correlated
with anti-GPIIb/IIIa antibody-producing B cell frequency (r 0.3,
p  0.005). Of 18 platelet eluate samples, 13 had a detectable level
of anti-GPIIb/IIIa antibodies, whereas plasma anti-GPIIb/IIIa an-
tibodies were undetectable in all cases. Serial analysis of a patient
with thrombocytopenia who responded to corticosteroid therapy
Table. Hematopoietic Support in Short-term Culture
CD45
Cell
Expansion
Percent
CD34,
Day 12
CFU/100
Input
Cells
CFU
Expansion
Percent
CD7,
Day 12
AdS 3.78  1.1
fold
17.4  5.1
%
12.2  2.8
CFU
0.90  0.3
fold
28.6  5.6
%
MdS 3.4  1.3
fold
28.7  6.5
%
16.3  3.7
CFU
1.07  0.27
fold
19.5  4.2
%
P 0.127 0.002 0.062 0.366 0.003
n 8 8 8 8 6
Values reported are the average  SEM, P values are by t-test.
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demonstrated an inverse correlation between platelet count and
anti-GPIIb/IIIa antibody-producing B cell frequency. Thrombo-
cytopenia mediated by anti-platelet antibodies should be included
into differential diagnosis for prolonged thrombocytopenia after
allo-HSCT.
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FEF25-75% AS A SPIROMETRIC VARIABLE IN PULMONARY FUNCTION
TESTING (PFT) IS PREDICTIVE FOR THE DIAGNOSIS OF OBLITERATIVE
BRONCHIOLITIS (OB) FOLLOWING MYELOABLATIVE ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Burgos-Fuster, L.M., Koyama, T., Milestone, A., Mineishi, S., Jagasia,
M., Vusirikala, M., Goodman, S., Schuening, F., Greer, J.P., Chinra-
tanalab, W., Brandt, S., Ruffner, K., Morgan, D.S., Stein, R.S.,
Kassim, A.A. Vanderbilt University Medical Center, Nashville, TN;
Veterans Affairs Medical Center, Nasville, TN
Introduction: Following allogeneic HSCT, a major cause of
obstruction is OB (frequency, 8-33%). Diagnosis is histologic, but
often presumptive, based on clinical features, radiographic and
PFT changes showing obstruction, hyperinﬂation and gas trap-
ping. OB is associated with chronic, but not acute graft-versus-host
disease (cGVHD/aGVHD). A 5% decline in percent predicted
forced expiratory volume in 1 second (FEV1), FEV1/FVC (forced
vital capacity)  0.7 or 10% fractional drop from previous best
PFT was suggestive of OB in previous studies. It is yet to be
deﬁned which spirometric measurement is most suggestive for the
presence of OB. Forced expiratory ﬂow rates (FEF25-75%), with
30% decline from baseline was found to be more sensitive than
FEV1 in diagnosing OB following single lung transplant [Nathan,
et al, 2003 J Heart and Lung Transplantation 22(4): 427]. FEF25-
75% has never been evaluated following allogeneic HSCT. Meth-
ods: We retrospectively reviewed PFT data on 48 adult patients
undergoing HSCT from 1998-2003, who survived for at least 12
months and had pre and post-transplant PFT within 1-year of
HSCT. Median age was 42 years (range, 20-57), and 54% were
male. Forty-seven patients had malignant hematologic disorders.
The conditioning regimen was TBI-based in 34 (73%) patients,
and 13 received chemotherapy only. Marrow and peripheral blood
stem cells were used in 22 and 26 patients respectively. Results:
Incidence of aGVHD was 52%, (gradeI-II/III-IV: 88%/12%),
12% of patients had cGVHD (limited/extensive: 69%/13%). Ten
patients (21%) had a diagnosis of OB (8-histologicaly, 2-based on
signs and symptoms). Spirometric measurements considered as
predictor variables included diffusion capacity for carbon monox-
ide (DLCO), FEV1, total lung capacity (TLC), FEF 25-75%.
There was no signiﬁcant association between diagnosis of OB and
age, GVHD, stem cell source, preparatory regimen, TLC or
DLCO. A backward elimination model building procedure for a
logistic regression identiﬁed FEF25-75% as the sole signiﬁcant
explanatory variable. This model suggests that with a 40% decrease
or more in FEF 25-75% compared to pre-transplant value, the
estimated probability of the diagnosis of OB would be 50% or
higher. Conclusion: A decrease in FEF 25-75% of  of 40%, in
the absence of other non-infectious pulmonary complications, was
highly suggestive in allogeneic HSCT patients for the diagnosis of
OB. We plan to evaluate our ﬁndings in a prospective study.
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PSYCHOSOCIAL PREDICTORS OF AUTOLOGOUS BONE MARROW
TRANSPLANT PATIENTS’ FUNCTIONING: INDICATIONS FOR EARLY IN-
TERVENTION
Lanza Hurley, C.1, Mumby, P.B.2, Di Iorio, S.2, Stiff, P.J.2 1. Loyola
University Chicago, Chicago, IL; 2. Loyola University Medical Center,
Maywood, IL
Compared to mixed oncology samples, estimates of emotional
distress are considered to be higher for patients treated by bone
marrow transplant (BMT). This increased risk has been met by
limited research investigating psychosocial predictors of BMT psy-
chological and physical sequelae. Such analysis may serve to better
inform bone marrow treatment centers in identiﬁcation of patients
at risk for transplant-related psychological and physical morbidity.
Data from 210 consecutive adult cancer patients who underwent
autologous BMT at a large Midwestern cancer center were uti-
lized. There were 73 males and 137 females (mean age  48.25).
Prior to transplant, patients completed a BMT clinic questionnaire
and the Symptom-Checklist 90-Revised (SCL-90-R). Stepwise
multiple regression analyses were performed using the depression
subscale of the SCL-90-R, coping, and total social support (i.e.,
structural and perceived) as dependent variables. Age and total days
from diagnosis to treatment were controlled. Gender predicted
depressive symptomatology (beta  .216, t  2.187, p  .03)
and total social support (beta  .206, t  2.084, p  .039), with
males endorsing more depressive symptoms than females and fe-
males listing more structural support than males. Marital status
predicted social support speciﬁc to BMT (beta  .368, t 
4.538, p  .001) with married patients reporting fewer supports
through BMT than their unmarried counterparts. Females re-
ported larger support networks than males. Previous psychological
treatment predicted depressive symptomatology (beta  6.165, t 
2.874, p  .005) and improved coping (beta  .493, t  3.766,
p  .001). That married persons mainly rely upon spouses for
support may have important caregiver respite implications. In
addition, psychotherapy may improve patients’ conﬁdence in their
ability to cope with BMT despite increased levels of depression
prior to BMT. These ﬁndings suggest early psychological inter-
ventions for patients undergoing BMT may improve coping re-
sources for dealing with the stress of the process. Further analyses
will investigate whether these psychosocial factors predict BMT-
related psychological and physical morbidity.
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PROSPECTIVE STUDY OF MAJOR SALIVARY GLANDS IN PATIENTS SUB-
MITTED TO BONE MARROW TRANSPLANTATION-PRELIMINARY RE-
SULTS
Coracin, F.L.1, Camargo, E.E.2, Vigorito, A.C.1, Gasparetto, P.F.1,
Peterson, D.E.3, Correa, M.E.P.1, De Souza, C.A.1 1. Hematology and
Blood Transfusion Center-State University of Campinas-UNICAMP,
Campinas, Sa˜o Paulo, Brazil; 2. Division of Nuclear Medicine-State
University of Campinas-UNICAMP, Campinas, Sa˜o Paulo, Brazil; 3.
School of Dental Medicine-University of Connecticut, Farmington, CT
Salivary gland involvement in chronic GVHD (cGVHD) is in-
dicated by increased dryness of the oral cavity, abnormalities in the
saliva and histopathological changes in labial minor salivary glands.
Salivary changes leading to 45-60% of hyposalivation have been
reported in cGVHD in both and human studies. Fibrosis and
inﬂammatory inﬁltration were the mostly important histopatho-
logical changes observed in oral cGVHD minor salivary glands
biopsies. The aim of this study was to evaluate prospectively the
side effects of the conditioning regimen used for allogeneic BMT
on major salivary gland using scintigraphy with Gallium-67 and
technetium-99m-pertechnetate. This is an ongoing study per-
formed in the University Hospital of State University of Campi-
nas–Brazil. Between March 2002 until July 2003, ﬁfteen Chronic
Myeloid Leukemia (CML) and three Severe Aplastic Anemia
(SAA) patients submitted to conventional allogeneic BMT were
enrolled. Ten of them are female and 8 are male and the median
age of this group was 39 yo (31-55 years). Conditioning regimen
and GVHD prophylaxis used following Institutional protocols.
Scintigraphic exams was performed at Division of Nuclear Medi-
cine, using 10mCi of Technetium-99m pertechnetate and 3mCi of
Gallium-67, intravenously. Gallium-67 images were done after 48
hours of intravenous injection. Gallium-67 and Technetium data
are summarized in Table 1 and Table 2, respectively. These data
are preliminary. Scintigraphy showed an increase of inﬂammatory
reaction and a functional deﬁcit in major salivary glands after
BMT. Salivary glands dysfunction maybe due to cGVHD or side-
effect related to high dose chemotherapy. It is not clear in the
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